Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lim, Sung Hee | - |
dc.contributor.author | Lee, Keun-Wook | - |
dc.contributor.author | Kim, Jae-Joon | - |
dc.contributor.author | Im, Hyeon-Su | - |
dc.contributor.author | Kim, In-Ho | - |
dc.contributor.author | Han, Hye Sook | - |
dc.contributor.author | Koo, Dong-Hoe | - |
dc.contributor.author | Cho, Jang Ho | - |
dc.contributor.author | Maeng, Chi Hoon | - |
dc.contributor.author | Lee, Min-Young | - |
dc.contributor.author | Lee, Hyo Jin | - |
dc.contributor.author | Kim, Jwa Hoon | - |
dc.contributor.author | Park, Sang Gon | - |
dc.contributor.author | Jung, Joo Young | - |
dc.contributor.author | Shin, Seong-Hoon | - |
dc.contributor.author | Kim, Ki Hyang | - |
dc.contributor.author | Kim, Hyeyeong | - |
dc.contributor.author | Oh, So Yeon | - |
dc.contributor.author | Kang, Minsu | - |
dc.contributor.author | Jung, Minkyu | - |
dc.contributor.author | Rha, Sun Young | - |
dc.date.accessioned | 2024-06-12T01:31:51Z | - |
dc.date.available | 2024-06-12T01:31:51Z | - |
dc.date.issued | 2024-02 | - |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/26328 | - |
dc.description.abstract | Background Immune checkpoint inhibitor (ICI) or irinotecan-based chemotherapy is frequently used after failure of second-line paclitaxel plus ramucirumab treatment for patients with locally advanced unresectable or metastatic advanced gastric cancer (AGC). This study aimed to compare the efficacy between ICI and irinotecan-based chemotherapy as third-line treatment in patients with AGC. Methods We retrospectively reviewed patients with AGC, whose third-line treatment started between July 2019 and June 2021 at 17 institutions in Korea. The ICI group included patients who received nivolumab or pembrolizumab, and the irinotecan-based chemotherapy group included patients who received irinotecan or FOLFIRI (5-fluorouracil, leucovorin and irinotecan). Results A total of 363 patients [n = 129 (ICI) and n = 234 (irinotecan-based chemotherapy)] were analyzed. The median progression-free survival was 2.3 and 2.9 months in ICI and irinotecan-based chemotherapy groups, respectively (p = 0.802). The median overall survival (OS) was 5.5 and 6.0 months in ICI and irinotecan-based chemotherapy groups, respectively (p = 0.786). For all patients included in this study, multivariable analysis showed that weight loss, peritoneal metastasis, low serum sodium or albumin, and short duration of second-line treatment were associated with inferior OS (p < 0.05). ICI showed significantly longer OS than irinotecan-based chemotherapy in patients without peritoneal metastasis. Whereas ICI showed significantly shorter OS in patients without PD-L1 expression than irinotecan-based chemotherapy. Conclusions No significant difference in survival outcome was observed between ICI and irinotecan-based chemotherapy as third-line treatment for AGC patients. ICI might be preferred for patients without peritoneal metastasis and irinotecan-based chemotherapy for patients with tumors without PD-L1 expression. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | BMC | - |
dc.title | Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06) | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1186/s12885-024-11972-w | - |
dc.identifier.scopusid | 2-s2.0-85186170268 | - |
dc.identifier.wosid | 001177035000008 | - |
dc.identifier.bibliographicCitation | BMC CANCER, v.24, no.1 | - |
dc.citation.title | BMC CANCER | - |
dc.citation.volume | 24 | - |
dc.citation.number | 1 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | EPSTEIN-BARR-VIRUS | - |
dc.subject.keywordPlus | GASTROESOPHAGEAL JUNCTION | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | SALVAGE CHEMOTHERAPY | - |
dc.subject.keywordPlus | BIWEEKLY IRINOTECAN | - |
dc.subject.keywordPlus | PLUS CHEMOTHERAPY | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | PHASE-III | - |
dc.subject.keywordPlus | FLUOROPYRIMIDINE | - |
dc.subject.keywordPlus | 5-FLUOROURACIL | - |
dc.subject.keywordAuthor | Gastric cancer | - |
dc.subject.keywordAuthor | Third-line treatment | - |
dc.subject.keywordAuthor | Irinotecan | - |
dc.subject.keywordAuthor | Nivolumab | - |
dc.subject.keywordAuthor | Pembrolizumab | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.